Humana (NYSE:HUM) Downgraded by Stephens to Equal Weight

by · The Cerbat Gem

Stephens downgraded shares of Humana (NYSE:HUM – Free Report) from an overweight rating to an equal weight rating in a research report released on Wednesday morning, Marketbeat reports. The firm currently has $250.00 price objective on the insurance provider’s stock, down from their previous price objective of $400.00.

HUM has been the subject of several other reports. Truist Financial raised their price objective on Humana from $355.00 to $400.00 and gave the stock a hold rating in a research note on Monday, July 15th. Oppenheimer increased their price target on Humana from $370.00 to $400.00 and gave the company an outperform rating in a research report on Thursday, August 1st. Deutsche Bank Aktiengesellschaft lifted their price target on Humana from $341.00 to $349.00 and gave the stock a hold rating in a research note on Friday, August 2nd. Cantor Fitzgerald reaffirmed a neutral rating and set a $395.00 price objective on shares of Humana in a research note on Tuesday. Finally, Piper Sandler assumed coverage on shares of Humana in a research report on Wednesday, June 26th. They issued an overweight rating and a $392.00 target price on the stock. One research analyst has rated the stock with a sell rating, sixteen have given a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of Hold and a consensus price target of $357.24.

View Our Latest Stock Report on HUM

Humana Price Performance

Shares of Humana stock opened at $240.03 on Wednesday. Humana has a 52 week low of $213.31 and a 52 week high of $530.54. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. The stock has a market cap of $28.92 billion, a PE ratio of 14.95, a price-to-earnings-growth ratio of 2.44 and a beta of 0.50. The company’s 50-day moving average price is $337.70 and its two-hundred day moving average price is $342.42.

Humana (NYSE:HUM – Get Free Report) last released its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping analysts’ consensus estimates of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The business had revenue of $29.54 billion for the quarter, compared to the consensus estimate of $28.52 billion. During the same period in the previous year, the firm earned $8.94 EPS. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Humana will post 16.01 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be paid a $0.885 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.54 annualized dividend and a dividend yield of 1.47%. Humana’s payout ratio is 22.04%.

Institutional Trading of Humana

A number of institutional investors have recently added to or reduced their stakes in HUM. J. W. Coons Advisors LLC lifted its stake in shares of Humana by 2.2% in the 4th quarter. J. W. Coons Advisors LLC now owns 2,775 shares of the insurance provider’s stock valued at $1,270,000 after purchasing an additional 60 shares during the last quarter. Blueshift Asset Management LLC bought a new position in Humana during the fourth quarter valued at about $228,000. Lake Street Advisors Group LLC acquired a new stake in shares of Humana in the fourth quarter worth about $440,000. Tower Research Capital LLC TRC boosted its stake in shares of Humana by 240.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 18,711 shares of the insurance provider’s stock worth $8,566,000 after acquiring an additional 13,209 shares in the last quarter. Finally, Crossmark Global Holdings Inc. increased its holdings in shares of Humana by 9.0% during the 4th quarter. Crossmark Global Holdings Inc. now owns 21,092 shares of the insurance provider’s stock valued at $9,657,000 after acquiring an additional 1,747 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

About Humana

(Get Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Stories